Clinical Trials Logo

Thyroid Eye Disease clinical trials

View clinical trials related to Thyroid Eye Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05776121 Active, not recruiting - Thyroid Eye Disease Clinical Trials

Study of ZB001 in Chinese Patients With Thyroid Eye Disease

Start date: May 10, 2023
Phase: Phase 1
Study type: Interventional

The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics(PK)/pharmacodynamics (PD) profile of ZB001 in Chinese patients with Thyroid Eye Disease.

NCT ID: NCT05176639 Active, not recruiting - Thyroid Eye Disease Clinical Trials

A Safety, Tolerability and Efficacy Study of VRDN 001 in Healthy Volunteers and Persons With Thyroid Eye Disease (TED)

Start date: December 3, 2021
Phase: Phase 3
Study type: Interventional

Please note that Phase 1/2 (HV & MAD) cohort - recruitment is completed and Phase 3 Component (THRIVE) - is actively recruiting. The investigational drug, VRDN-001, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). This clinical trial will evaluate the safety, tolerability and pharmacokinetics (the concentration of drug in the blood over time) of VRDN-001 in healthy volunteers and in patients with TED. Study participants with TED will also be evaluated over time for changes in their signs and symptoms of TED compared to their baseline measurements.

NCT ID: NCT05002998 Active, not recruiting - Thyroid Eye Disease Clinical Trials

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Start date: September 16, 2021
Phase: Phase 4
Study type: Interventional

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants. This international, Phase 3b/4 trial is being conducted to fulfill an FDA post-marketing requirement for a descriptive trial to evaluate the safety, efficacy and need for re-treatment of 3 different teprotumumab treatment durations for TED. In addition, serum samples from participants with a Baseline Clinical Activity Score (CAS) ≥3 will be evaluated for biomarkers of disease.